Default Category
-
Godiva Japan: Think Local, Scale Global
Deshpande, Rohit; Cekin, Esel; Kanno, AkikoCase HBS-517056-EMarketingThis case tracks Jerome Chouchan's strategies and execution for a successful turn around of Godiva Japan's operations which was experiencing a decline in sales when he became the managing director of the company in 2010. Through various initiatives and innovations, Godiva Japan had targeted a variety of demographic segments in different sales points, acquired new customers and created a moment of luxurious consumption for all ages. Accordingly, w...Starting at €8.20
-
Amgen Inc.: Pursuing Innovation and Imitation? (A)
Mackenzie, Ian WCase HBS-714424-EStrategySet in 2009, the (A) case explores whether Amgen, a leading innovator of biotech-based drugs, should enter the emerging business of biosimilars (BS), which are essentially 'me-too' products. There appear to be sound reasons to explore this related diversification: innovation is getting harder, regulators are intent on encouraging BS, and Amgen needs renewed growth. But the possibility sparked a strong negative reaction within Amgen, not least bec...Starting at €8.20
-
Uber and the Taxi Industry (A)
Casadesus-Masanell, Ramon; Mackenzie, Ian W; Dadiomov, DimitriCase HBS-715433-EStrategyStarting at €8.20
-
UberX & Lyft (B)
Casadesus-Masanell, Ramon; Mackenzie, Ian W; Dadiomov, DimitriCase HBS-715434-EStrategySupplement case for 715433.Starting at €5.74
-
Pursuing Innovation and Imitation? (A) (Spanish version)
Mackenzie, Ian WCase HBS-719S12Strategyinnovation is getting harder, regulators are intent on encouraging BS, and Amgen needs renewed growth. But the possibility sparked a strong negative reaction within Amgen, not least because it contravened Amgen's mission. Internal debate was exacerbated by the presence of considerable uncertainty over the regulatory requirements for BS development and how difficult it would be to develop a BS. Some felt it played to Amgen's strengths, others fel...Starting at €8.20
-
FANUC Corporation: Reassessing the Firm's Governance and Financial Policies
Esty, Benjamin C.; Sato, Nobuo; Kanno, AkikoCase HBS-216042-EFinanceIn February 2015, Daniel Loeb (a US-based activist investor) announced his firm had a large investment in FANUC Corporation, a leading producer of industrial robots and software for machine tools. Loeb was demanding that the Japanese firm change its finanStarting at €8.20
-
Amgen Inc.: Pursuing Innovation and Imitation (B)
Mackenzie, Ian WCase HBS-714426-EStrategyThe (B) case reveals that Sharer decided that Amgen should the emerging biosimilars business. However, he took the better part of a year to syndicate the decision across the senior team while in parallel investing in some time-critical process development. The (B) case then focuses on how the new business should be implemented, particularly in terms of integration versus separation of a new business unit, choice of unit leader, and whether Amgen ...Starting at €5.74
-
Oriental Land Co., Ltd. -Tokyo Disney Resort
Casadesus-Masanell, Ramon; Kanno, AkikoCase HBS-720460-EStrategyThis case describes the history of Oriental Land Co. Ltd.'s (OLC's) Tokyo Disney Resort (TDR), its operations, the extent of vertical integration, and the challenges it faced in 2018 as OLC's chairman and CEO, Toshio Kagami, contemplated how best to dealStarting at €8.20
-
Uber y la industria del Taxi (A)
Casadesus-Masanell, Ramon; Mackenzie, Ian W; Dadiomov, DimitriCase HBS-716S07StrategyStarting at €8.20
-
Restructuring JAL
Baker, Malcolm P.; Sunderam, Adi; Sato, Nobuo; Kanno, AkikoCase HBS-214055-EFinanceHideo Seto, the recently appointed chairman of the investment committee of the Enterprise Turnaround Initiative Corporation, must decide whether to push JAL group, Japan's largest airline, into bankruptcy or to act as a sponsor in an out-of-court restructStarting at €8.20